FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017153914> ?p ?o ?g. }

• W2017153914 endingPage "e43903" @default.
• W2017153914 startingPage "e43903" @default.
• W2017153914 abstract "The RV144 clinical trial showed for the first time that vaccination could provide modest but significant protection from HIV-1 infection. To understand the protective response, and to improve upon the vaccine's efficacy, it is important to define the structure of the immunogens used in the prime/boost regimen. Here we examined the heterogeneity in net charge, attributable to glycoform variation, of the gp120 immunogens contained in the AIDSVAX B/E vaccine.Isoelectric focusing and glycosidase digestion were used to assess variation in net charge of the gp120s contained in the AIDSVAX B/E vaccine used in the RV144 trial. We observed 16 variants of MN-rgp120 and 24 variants of A244-rgp120. Glycoform variation in gp120 produced in Chinese hamster ovary cells was compared to glycoform variation in gp120 produced in the 293F human embryonic kidney cell line, often used for neutralization assays. We found that gp120 variants produced in CHO cells were distinctly more acidic than gp120 variants produced in 293 cells. The effect of glycoform heterogeneity on antigenicity was assessed using monoclonal antibodies. The broadly neutralizing PG9 MAb bound to A244-rgp120, but not to MN-rgp120, whether produced in CHO or in 293. However, PG9 was able to bind with high affinity to MN-rgp120 and A244-rgp120 produced in 293 cells deficient in N-acetylglucosaminyltransferase I.MN- and A244-rgp120 used in the RV144 trial exhibited extensive heterogeneity in net charge due to variation in sialic acid-containing glycoforms. These differences were cell line-dependent, affected the antigenicity of recombinant envelope proteins, and may affect assays used to measure neutralization. These studies, together with recent reports documenting broadly neutralizing antibodies directed against carbohydrate epitopes of gp120, suggest that glycoform variation is a key variable to be considered in the production and evaluation of subunit vaccines designed to prevent HIV infection." @default.
• W2017153914 created "2016-06-24" @default.
• W2017153914 creator A5011301380 @default.
• W2017153914 creator A5037878942 @default.
• W2017153914 creator A5061035808 @default.
• W2017153914 creator A5079157586 @default.
• W2017153914 creator A5089825041 @default.
• W2017153914 date "2012-08-22" @default.
• W2017153914 modified "2023-10-15" @default.
• W2017153914 title "Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials" @default.
• W2017153914 cites W1496960594 @default.
• W2017153914 cites W1505517942 @default.
• W2017153914 cites W1601713328 @default.
• W2017153914 cites W1676407394 @default.
• W2017153914 cites W1794879226 @default.
• W2017153914 cites W1971601938 @default.
• W2017153914 cites W1974887619 @default.
• W2017153914 cites W1977243656 @default.
• W2017153914 cites W1985711808 @default.
• W2017153914 cites W1993052631 @default.
• W2017153914 cites W1995466180 @default.
• W2017153914 cites W1997677784 @default.
• W2017153914 cites W2000475809 @default.
• W2017153914 cites W2012456268 @default.
• W2017153914 cites W2015349792 @default.
• W2017153914 cites W2023886845 @default.
• W2017153914 cites W2033722707 @default.
• W2017153914 cites W2043521256 @default.
• W2017153914 cites W2049324939 @default.
• W2017153914 cites W2049836668 @default.
• W2017153914 cites W2051364248 @default.
• W2017153914 cites W2056098664 @default.
• W2017153914 cites W2059474578 @default.
• W2017153914 cites W2072857369 @default.
• W2017153914 cites W2074969682 @default.
• W2017153914 cites W2083726777 @default.
• W2017153914 cites W2087859193 @default.
• W2017153914 cites W2092325349 @default.
• W2017153914 cites W2094945468 @default.
• W2017153914 cites W2096409198 @default.
• W2017153914 cites W2113236498 @default.
• W2017153914 cites W2122617162 @default.
• W2017153914 cites W2124445678 @default.
• W2017153914 cites W2124935744 @default.
• W2017153914 cites W2128519954 @default.
• W2017153914 cites W2128579789 @default.
• W2017153914 cites W2131903471 @default.
• W2017153914 cites W2133233128 @default.
• W2017153914 cites W2142470167 @default.
• W2017153914 cites W2143421242 @default.
• W2017153914 cites W2146981871 @default.
• W2017153914 cites W2149132834 @default.
• W2017153914 cites W2150953958 @default.
• W2017153914 cites W2151393720 @default.
• W2017153914 cites W2152048324 @default.
• W2017153914 cites W2152640863 @default.
• W2017153914 cites W2153576963 @default.
• W2017153914 cites W2160708858 @default.
• W2017153914 cites W2161157573 @default.
• W2017153914 cites W2165233066 @default.
• W2017153914 cites W2172055214 @default.
• W2017153914 cites W2338567969 @default.
• W2017153914 doi "https://doi.org/10.1371/journal.pone.0043903" @default.
• W2017153914 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3425498" @default.
• W2017153914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22928048" @default.
• W2017153914 hasPublicationYear "2012" @default.
• W2017153914 type Work @default.
• W2017153914 sameAs 2017153914 @default.
• W2017153914 citedByCount "29" @default.
• W2017153914 countsByYear W20171539142013 @default.
• W2017153914 countsByYear W20171539142014 @default.
• W2017153914 countsByYear W20171539142015 @default.
• W2017153914 countsByYear W20171539142016 @default.
• W2017153914 countsByYear W20171539142017 @default.
• W2017153914 countsByYear W20171539142018 @default.
• W2017153914 countsByYear W20171539142019 @default.
• W2017153914 countsByYear W20171539142020 @default.
• W2017153914 countsByYear W20171539142023 @default.
• W2017153914 crossrefType "journal-article" @default.
• W2017153914 hasAuthorship W2017153914A5011301380 @default.
• W2017153914 hasAuthorship W2017153914A5037878942 @default.
• W2017153914 hasAuthorship W2017153914A5061035808 @default.
• W2017153914 hasAuthorship W2017153914A5079157586 @default.
• W2017153914 hasAuthorship W2017153914A5089825041 @default.
• W2017153914 hasBestOaLocation W20171539141 @default.
• W2017153914 hasConcept C104317684 @default.
• W2017153914 hasConcept C14086860 @default.
• W2017153914 hasConcept C153911025 @default.
• W2017153914 hasConcept C159047783 @default.
• W2017153914 hasConcept C159654299 @default.
• W2017153914 hasConcept C175656101 @default.
• W2017153914 hasConcept C203014093 @default.
• W2017153914 hasConcept C22070199 @default.
• W2017153914 hasConcept C2522874641 @default.
• W2017153914 hasConcept C2778190748 @default.
• W2017153914 hasConcept C2778575167 @default.
• W2017153914 hasConcept C2779026604 @default.
• W2017153914 hasConcept C2780195530 @default.

• next